Researchers at Stanford have discovered new, chemically distinct opioid receptor ligands that may be used to develop safer opioid therapeutics. Opioids are ligands that bind to the mu, delta, and/or kappa opioid receptors.
Stanford and Rockefeller researchers have identified and developed dynein-specific inhibitors that have significant medical applications involving mitotic spindle assembly, organelle transport, and primary cilia formation.